SCHEMBL19716352

SCHEMBL19716352

CC1(NCC(F)F)CCN(C(=O)OCc2ccccc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
NPSR1 Q6W5P4 2/20 0.51
SMN1; SMN2 Q16637 3/20 0.50
KDM1A O60341 3/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
HDAC1 Q13547 3/20 0.48
HDAC6 Q9UBN7 3/20 0.48
HDAC3 O15379 2/20 0.48
HDAC2 Q92769 2/20 0.48
CYP2C19 P33261 1/20 0.48
HTT P42858 1/20 0.47
OPRD1 P41143 1/20 0.45
OPRK1 P41145 1/20 0.45
GRIN2B Q13224 3/20 0.44
ENPP2 Q13822 1/20 0.44
ATXN2 Q99700 1/20 0.44
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7495274 0.81 MEN1 (0.54) MEN1KMT2ANPSR1SMN1; SMN2KDM1A
SCHEMBL28474414 0.81 MEN1 (0.59) MEN1KMT2ANPSR1SMN1; SMN2KDM1A
SCHEMBL22660544 0.80 MEN1 (0.47) MEN1KMT2ANPSR1SMN1; SMN2KDM1A
SCHEMBL566838 0.79 MEN1 (0.61) MEN1KMT2ANPSR1SMN1; SMN2KDM1A
SCHEMBL30967382 0.79 MEN1 (0.54) MEN1KMT2ANPSR1SMN1; SMN2KDM1A
SCHEMBL31094792 0.79 MEN1 (0.57) MEN1KMT2ANPSR1SMN1; SMN2KDM1A
SCHEMBL16980454 0.79 MEN1 (0.57) MEN1KMT2ANPSR1SMN1; SMN2KDM1A
SCHEMBL31714031 0.79 HDAC1 (0.48) MEN1KMT2ANPSR1SMN1; SMN2KDM1A
SCHEMBL631455 0.78 MEN1 (0.59) MEN1KMT2ANPSR1SMN1; SMN2KDM1A
SCHEMBL31468184 0.78 MEN1 (0.59) MEN1KMT2ANPSR1SMN1; SMN2KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3468953-B1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE IP DEV LTD (GB) 2024-05-22 EP disclosed
CN-109563043-B Substituted pyridines as inhibitors of DNMT1 葛兰素史密斯克莱知识产权发展有限公司 2022-05-31 CN disclosed
US-10975056-B2 Substituted pyridines as inhibitors of DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-04-13 US disclosed
US-20190194166-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-06-27 US disclosed
EP-3468953-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GlaxoSmithKline Intellectual Property Development Limited (GB) 2019-04-17 EP disclosed
WO-2017216726-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-12-21 WO disclosed
WO-2017216727-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10975056-B2 Substituted pyridines as inhibitors of DNMT1 DNMT1, DNMT3A, DNMT3B MEN1 1594/4885KMT2A 121/4885NPSR1 2044/4885
US-20190194166-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 DNMT1, DNMT3A, DNMT3B MEN1 1594/4885KMT2A 121/4885NPSR1 2044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.